Abstract Genome-wide association studies (GWASs) have reported numerous associations between risk variants and Alzheimer's disease (AD). However, these associations do not necessarily indicate a causal relationship. If the risk variants can be demonstrated to be biologically functional, the possibility of a causal relationship would be increased. In this article, we reviewed all of the published GWASs to extract the genome-wide significant (p \ 5910 -8 ) and replicated associations between risk variants and AD or ADbiomarkers. The regulatory effects of these risk variants on the expression of a novel class of non-coding RNAs (piRNAs) and protein-coding RNAs (mRNAs), the alteration of proteins caused by these variants, the associations between AD and these variants in our own sample, the expression of piRNAs, mRNAs and proteins in human brains targeted by these variants, the expression correlations between the risk genes and APOE, the pathways and networks that the risk genes belonged to, and the possible long non-coding RNAs (LncRNAs) that might regulate the risk genes were analyzed, to investigate the potential biological functions of the risk variants and explore the potential mechanisms underlying the SNP-AD associations. We found replicated and significant associations for AD or AD-biomarkers, surprisingly, only at 17 SNPs located in 11 genes/snRNAs/LncRNAs in eight genomic regions. Most of these 17 SNPs enriched some AD-related pathways or networks, and were potentially functional in regulating piRNAs and mRNAs; some SNPs were associated with AD in our sample, and some SNPs altered protein structures. Most of the protein-coding genes regulated by the risk SNPs were expressed in human brain and correlated with APOE expression. We conclude that these variants were most robust risk markers for AD, and their contributions to AD risk was likely to be causal. As Xiaoyun Guo and Wenying Qiu contributed equally to this work.
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Introduction
Alzheimer's disease (AD) is the most common cause of dementia. It affects several millions of people worldwide. It is a primary neurodegenerative cerebral disease in the elderly, characterized by two major histopathologic changes in the brain, i.e., extracellular amyloid plaques that are composed of Ab40 and Ab42 and intracellular neurofibrillary tangles (NFT) that are composed of hyperphosphorylated protein Tau (Masters et al. 1985) . The core cerebrospinal fluid (CSF) biomarkers for the diagnosis of AD include Ab42 (amyloid-42 peptide), T-tau (total tau), and P-tau (phosphorylated tau) (Anoop et al. 2010) .
From 2007 till July, 2017, 1055 genome-wide association studies (GWASs) and whole genome/exome sequencing studies of AD or AD-biomarkers have been published. However, the vast majority of these studies produced results that were not significant at genome-wide level and/or were not replicated by any other study, and thus might confuse or even mislead the readers. Although some studies reported ''replicable'' findings at gene level (i.e., different risk markers from the same gene), the replicable findings at individual marker level (i.e., same risk markers) were not common. Here, we only followed up the latter, which we believe can really be called ''replicated'' and more conservative, robust and reliable than the ''gene-level'' findings.
In this article, we reviewed all of these published studies, and extracted the most robust, i.e., both genome-wide significant (p \ 5910 -8 ) and replicated, associations between risk SNPs and AD or AD-biomarkers. These associations themselves do not necessarily indicate a cause-effect relationship. However, if we can demonstrate that the risk SNPs are biologically functional, these associations are more likely to be causal ones. Thus, in this study, a series of functional analyses were conducted based on the pathway illustrated in Fig. 1 .
Summary of materials and methods (much detailed in the Supplementary Materials)
All associations between SNPs and AD/AD-biomarkers screened from the published literatures that are genomewide significant (p \ 5910 -8 ) and replicated across at least two independent studies are summarized in Table 1 . These risk SNPs were genotyped in our own small cohort (6 AD and 6 controls) to replicate the SNP-AD association (Qiu et al. 2017) , which was approved by the ethics committee of The Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences.
To explore the potential biological functions of these risk SNPs, we predicted their various functions using a series of bioinformatics analyses, and examined the potential regulatory effects of these SNPs on RNA expression using real molecular experiment, including the expression of the protein-coding mRNAs and the largest class of non-coding RNAs, i.e., piRNAs. The whole set of analyses was based on a regulation pathway illustrated in Fig. 1 .
For the mRNA expression, the genes that these risk SNPs are located were studied and the cis-regulatory effects of these SNPs on the mRNAs in human brains of a European cohort (n = 134) were examined. For the piRNA expression, the transcriptome-wide piRNAs in human brains of our small Chinese cohort (6 AD and 6 controls; see above) were studied (Qiu et al. 2017 ) and the trans-regulatory effects of these SNPs on the piRNAs were examined. Furthermore, the expression of mRNAs and proteins encoding by these risk genes were examined in multiple brain regions in multiple independent European and American cohorts, the correlations between their mRNA expression and the APOE expression in brain were tested, and the most possible phenotype that these risk genes can predict for was explored using pathway/network analysis. Finally, the long non-coding RNAs (LncRNAs) proximate to these risk genes were explored. Integrating multiple independent pieces of positive evidence from these analyses would increase the possibility that the SNP-AD relationships are causal and suggest the potential mechanisms underlying these SNP-AD associations.
July, 2017, surprisingly, we could only extract the associations of 17 variants located in 11 genes/snRNAs/ LncRNAs in eight loci from 28 studies that were genomewide significant (1.0 9 10 -295 B p B 9.0 9 10 -9 ) and replicated across at least two independent studies (not only two independent samples in the same study) at single-point level. These eight loci include APOE cluster (NECTIN2-TOMM40-APOE-APOC1) (Abraham et al. 2008; Logue et al. 2011; Naj et al. 2010; Antunez et al. 2011; Feulner et al. 2010; Kim et al. 2011; Harold et al. 2009; Lambert et al. 2009; Nelson et al. 2014; Heinzen et al. 2010; Seshadri et al. 2010; Perez-Palma et al. 2014; Shen et al. 2010; Meda et al. 2012; Ramirez et al. 2014; Ramanan et al. 2014; Melville et al. 2012; Kamboh et al. 2012b; Li et al. 2008; Webster et al. 2008; Coon et al. 2007; Kamboh et al. 2012a) , APOJ (Lambert et al. 2009; Jun et al. 2016; Lambert et al. 2013) , SORL1 (Miyashita et al. 2013; Lambert et al. 2013; Jun et al. 2016) , SLC24A4 (Jun et al. 2016; Lambert et al. 2013 ), CR1 (Lambert et al. 2009 , CD33 (Naj et al. 2011; Lambert et al. 2013 ), LOC105373605 (Kamboh et al. 2012b Naj et al. 2011; Lambert et al. 2013; Jun et al. 2016; Hollingworth et al. 2011; Antunez et al. 2011; Hu et al. 2011) and RNU6-560P (Lambert et al. 2013; Jun et al. 2016; Harold et al. 2009) (Table 1) , which is highly consistent with the gene list presented in the largest GWAS meta-analysis (Lambert et al. 2013) . Among them, the associations between AD and variants (rs6859, rs157580, rs2075650, rs429358 and rs4420638) within APOE cluster are most robust. The associations between AD and rs6859 and rs157580 were replicated across three GWASs (8 9 10 -89 B p B 6 9 10 -14 ) (Abraham et al. 2008; Logue et al. 2011; Naj et al. 2010; Antunez et al. 2011; Feulner et al. 2010; Kim et al. 2011) ; the associations between either AD or age-ofonset of AD and rs4420638 were replicated across five GWASs (8 9 10 -149 B p B 1 9 10 -12 ) (Kamboh et al. 2012a (Kamboh et al. , 2012b Coon et al. 2007; Li et al. 2008; Webster et al. 2008) ; the associations between AD and rs2075650 were replicated across nine GWASs (1 9 10 -295 B p B 3 9 10 -11 ) (Harold et al. 2009; Lambert et al. 2009; Nelson et al. 2014; Heinzen et al. 2010; Seshadri et al. 2010; Perez-Palma et al. 2014; Naj et al. 2010; Kim et al. 2011; Shen et al. 2010) ; and the associations between AD or AD biomarkers (Ab 42 , t-tau, p-tau181p, hippocampal, amygdalar or total cerebral volume) and rs429358 ? rs7412 (e2/e3/e4) were replicated across eight GWASs (2 3 10 233 £ p£4 3 10 29 ) (Meda et al. 2012; Kim et al. 2011; Ramirez et al. 2014; Ramanan et al. 2014; Melville et al. 2012; Shen et al. 2010) . Some of these associations have been validated by previous functional studies. Basically, other surrounding markers that might be in linkage disequilibrium with these 17 SNPs have not been reported to be genome-wide significant, replicated across studies or biologically functional (data not shown). Finally, more other phenotypes associated with these genes and the molecular functions of these genes are presented in Supplementary Table S1 .
Bioinformatics analysis
Among the 17 risk SNPs in 
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-6 } (Shen et al. 2010) in the development of AD. 
The risk variants may regulate the expression of risk genes in human brains
Cis-eQTL analysis showed that most SNPs had nominal cis-acting regulatory effects on mRNA expression (p \ 0.05). The effect of rs6656401 on CR1 in HIPP (p = 2.7 9 10 -5 ) and WHMT (p = 6.5 9 10 -7 ), and the effects of rs2279590 and rs9331896 on APOJ in TCTX (p = 1.3 9 10 -4 and 4.5 9 10 -4 , respectively) and WHMT (p = 1.4 9 10 -4 and 1.5 9 10 -4 , respectively) remained significant after Bonferroni correction. (Table 2 ).
The risk variants may regulate the expression of piRNAs in brains
We found difference in genotype frequency of rs2075650 at APOE cluster (A/G genotype frequency: 0.714 vs. 0.111; p = 0.029) and allele frequency (G allele frequency: 0.357 vs. 0.056; p = 0.055) between AD cases and controls in our small cohort. The association between this marker and AD or AD-biomarkers has been reported to be the most robust one in literatures. It has been reported to be extremely significant (with lowest p values) and has been replicated across nine (the highest number) independent GWASs (Table 1) . Our small cohort had 35% of power (calculated by an R program pwr.chisq.test) to detect this association based on the most significant finding reported previously (Seshadri et al. 2010) .
eQTL analysis showed that some risk SNPs had transcriptome-wide significant (p \ 5.3 9 10 -6 ) regulatory effects on piRNAs (Table 3) , including rs10792832 and rs3851179 at RNU6-560P and e2/e3/e4 at APOE (9.4 9 10 -8 B p B 4.7 9 10 -6 ). (Table 3) .
mRNA/Protein expression of risk genes in human brain
Except for CR1 and CD33, other seven protein-coding genes, including APOJ, SORL1, SLC24A4, NECTIN2, The SNP list refers to Table 1 Brain regions: frontal cortex (FCTX), temporal cortex (TCTX), occipital cortex (specifically primary visual cortex, OCTX), putamen (PUTM), thalamus (THAL), hippocampus (HIPP), substantia nigra (SNIG), and intralobular white matter (WHMT). * The effects remaining significant after Bonferroni correction are bold, i.e., p \ a = 2.0 9 10 -4 = 0.05/(10 brain tissues 9 25 regulations) 2.8 9 10 The expression of eight protein-coding genes was correlated with APOE expression
The mRNA expression of all eight risk genes in brain was significantly correlated with APOE expression in at least one of the ten brain regions in the UK European cohort (0.29 B |r| B 0.81; 2.9 9 10 -32 B p B 6.2 9 10 -4 ), and APOJ, SORL1, APOE and APOC1 belong to the same lipoprotein metabolism pathway (www.reac tome.org). Except for the negative correlations (r \ 0) between SORL1 and APOE in OCTX, FCTX and TCTX Brain regions: whole brain (WHOL), cortex (CTX), prefrontal cortex (PFCX), anterior cingulate cortex (ACTX), cerebellar cortex (CRTX), hypothalamus (HPTH), nucleus accumbens (NACC), caudate nucleus (CDNL), medulla (specifically inferior olivary nucleus, MEDU), amygdala (AMYG), cerebellar hemisphere (CRHM), pituitary (PITT), cerebellum peduncles (CRPD), dorsal root ganglion (DRGL), fetal brain (FTBR), pons (PONS), and pineal (PINL). Other abbreviations refer to Table 2 and between SLC24A4 and APOE in OCTX, all others were positive (r [ 0) (Table 5) .
Gene network and pathway analysis
Overrepresentation analysis using IPA identified biological pathways containing a statistically significant excess of these genes. The top 5 canonical pathways found to be overrepresented in these genes using IPA are shown in Table 6 . Two canonical pathways related to the retinoid X receptor were the most significant enriched pathways: LXR/RXR Activation (p = 1.50 9 10 -5 ) and FXR/RXR Activation pathways (p = 1.72 9 10 -5 ). These were followed by Atherosclerosis Signaling (p = 1.74 9 10 -5 ), IL-12 Signaling and Production in Macrophages (p = 2.64 9 10 -5 ), and Production of Nitric Oxide and Reactive Oxygen Species in Macrophages (p = 6.07 9 10 -5 ) pathaways. Late-onset AD (p = 1.75 9 10 -10 ), efflux of phospholipid (p = 1.92 9 10 -7 ), AD (p = 2.20 9 10 -7 ), familial amyloidosis (p = 4.48 9 10 -7 ), lattice corneal dystrophy type I (p = 4.84 9 10 -7 ) were the top enriched diseases and functions. Only the network for Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry was significantly enriched (Score = 23). IPA knowledge base significantly associated this network to both late-onset AD (p = 1.75 9 10 -10 ), and AD (p = 2.20 9 10 -7 ) as shown in Fig. 2 . Current network and pathway analysis is limited by the state of current knowledge about gene interactions and functions in the biomedical literature. Thus, well studied genes have more complete, validated interaction and functional data in contrast to less studied ones. In this regard, these results represent our findings with respect to the current state of knowledge.
The LncRNAs related to the replicated risk genes
The LncRNAs proximate to each gene are listed in Table 7 . One sense LncRNA 2.9 kb to SLC24A4 is a large intergenic non-coding RNA (LincRNA), with a length of 15 kb; three others overlapping with or close to SORL1 and CD33 are antisense LncRNAs, with lengths of 12-31 kb. The results presented above are also illustrated in Fig. 1 .
Discussion
More than 10,000 genetic studies of AD have been published so far, and over 560 genes have been ''associated'' with AD risk, which might confuse the readers and some might mislead them due to the non-replicability issue. Our analysis first explicitly showed that, after stringent screening, only 17 SNPs in eight loci were robustly The abbreviations of brain regions refer to Table 4 . r correlation coefficient; a = 6.3 9 10 -4 = 0.05/(10 brain tissues 9 8 genes); any correlation with p [ a is not listed in this table associated with AD; that is, these SNPs were biologically functional and potentially causal, and their associations with AD were genome-wide significant and replicated across independent studies. Most of these eight loci enriched some AD-related pathways or networks. We believe these SNPs/loci should have the highest possibility of contribution to AD risk. APOE and the lipoprotein metabolism pathway possess the highest weight among this contribution, as expected though. These risk SNPs/loci contribute to AD risk probably via common or distinct mechanisms. These mechanisms may be related to the direct or indirect regulatory functions of the risk variants. We illustrate possible mechanisms underlying these SNP-AD associations in Fig. 1 . The cis-eQTL and bioinformatics analyses provided evidence to support that these replicated risk SNPs might be biologically functional in regulating piRNAs and mRNAs, altering protein structures, and influencing the transcription, expression and splicing of the risk genes. Many piRNAs, mRNAs and proteins targeted by these variants were expressed in human brains. This evidence increased the possibility that these risk SNPs might play functional roles in AD development.
As expected, association between APOE and AD has been intensively reported and is most robust. APOE is highly abundant in human brains. It may be directly involved in AD pathology or indirectly through a b-amyloid (Ab) or tau pathway (Puglielli et al. 2003; Namba et al. 1991; Lilius et al. 1999) . Six other protein-coding risk genes, including APOJ, SORL1, SLC24A4, NECTIN2, TOMM40 and APOC1, were significantly expressed in multiple human brain regions too. They were all correlated with APOE in expression. NECTIN2, TOMM40 and APOC1 are closely located within the same genomic cluster as APOE. APOJ, SORL1 and APOC1 belong to the same lipoprotein metabolism pathway (www.reactome.org) as APOE too. This pathway is critical in redistributing cholesterol and phospholipids in brains, responsible for the apoE4-associated neuropathology including the formation of neurotoxic fragments that have been demonstrated to be involved in the development of AD (Mahley 2016; Jones et al. 2010) . APOE and APOJ expression in brains is the most abundant among all risk genes for AD. Apparently, APOE and the lipoprotein metabolism pathway possess the highest weight in contribution to the AD risk. Moreover, SLC24A4 is involved in neural development (Larsson et al. 2011) . RIN3 next to SLC24A4 interacts with BIN1 in the early endocytic pathway (Kajiho et al. 2003) , and BIN1 is another well-known risk gene for AD, which is probably the alternative non-APOE pathway via which SLC24A4 is implicated in AD (Tan et al. 2013) .
The protein-coding risk gene CD33 was expressed a little bit lower than the threshold in brains in our four independent brain tissue cohorts (data not shown). However, this low expression was significantly correlated with APOE expression in SNIG and TCTX in our cohorts, and literatures have also reported low expression of CD33 around the threshold mainly in microglial cells (Jiang et al. 2014) , which suggested it might still be able to play a direct functional role in AD too. CD33 can inhibit the uptake and clearance of Ab42 in microglial cells and CD33 inactivation can mitigates Ab pathology (Griciuc et al. 2013) . CD33 was associated with accumulation of neuritic amyloid pathology and fibrillar amyloid, and increased numbers of activated human microglia (Bradshaw et al. 2013) .
The protein-coding risk gene CR1 (i.e., CD35) was expressed much lower than the threshold in brains in our four independent brain cohorts (data not shown), consistent with previous reports (Fonseca et al. 2016 ). However, this very low expression was also significantly correlated with APOE expression in multiple brain regions in our cohorts. Some studies have also reported low expression of CR1 in some brain regions (Chibnik et al. 2011; Bralten et al. 2011) , and CR1 interacted with APOE and participated in the clearance of b amyloid (Ab) peptide. Ab is the principal constituent of amyloid plaques that is one of the major brain lesions of individuals with AD (Thambisetty et al. 2013; Lambert et al. 2009; Biffi et al. 2012) .
Additional functional pathway and network analysis with IPA suggested that more other pathways that these risk genes belong to might also be involved in AD. The top most significant canonical pathways resulting from the enrichment analysis were related to the retinoid X receptors (RXRs). Recent studies have pointed to a role of liver X receptor, a RXR binding partner, in the AD pathophysiology (Sandoval-Hernandez et al. 2015) . The third most significant enriched canonical pathway was Atherosclerosis signaling. The association between cerebrovascular atherosclerosis and AD has been examined in many crosssectional studies (Kim et al. 2016) . Both Atherosclerosis and AD involve inflammation and macrophage infiltration (Lathe et al. 2014 ). Subsequently, two canonical pathways indicative of macrophage activation [production of IL-12 and nitric oxide and reactive oxygen species (NOROS)] were among the top 5 significantly enriched pathways. The NOROS pathway was listed as top 1 by a previous report Sense LncRNAs are transcribed from the same genomic strand as the protein-coding mRNAs, Antisense LncRNAs are transcribed from the antisense strand (Li et al. 2015) . Finally, if analyzed using MetaCore, the top 4 significantly enriched canonical pathways were all ''immune response'' pathways (data not shown), consistent with a previous report (Jones et al. 2010) . Recent evidence suggests that piRNAs are abundant in the brain (Mani and Juliano 2013; Rajasethupathy et al. 2012; Lee et al. 2011; Sharma et al. 2001; Perrat et al. 2013; Yan et al. 2011; Ghildiyal et al. 2008; Dharap et al. 2011; Peng and Lin 2013; Zuo et al. 2016b; Qiu et al. 2017) . piRNAs may regulate the mRNAs and translation of the proximate risk genes (Grivna et al. 2006) or interact with neurotransmitters in brains (Ross et al. 2014; Rajasethupathy et al. 2012) , and thus may play roles in brain disorders. Our transcriptome-wide eQTL screening demonstrated that the risk SNPs, especially in non-coding loci, might have transregulatory effects on piRNAs, which may suggest a novel mechanism underlying the SNP-disease associations.
Finally, five risk variants are located within or close to either an antisense LncRNA (i.e., LOC105373605) or a snRNA that does not encode any protein. These LncRNA and snRNA are proximate to BIN1 and PICALM, respectively. BIN1 and PICALM are expressed in human brains and have widely been associated with AD by numerous studies (Wang et al. 2016; Holler et al. 2014) . The antisense LncRNA and snRNA might use diverse transcriptional and post-transcriptional mechanisms (Faghihi and Wahlestedt 2009; Villegas and Zaphiropoulos 2015; Zuo et al. 2016a ) to regulate BIN1 and PICALM, respectively, to play roles in AD. PICALM and BIN1 were modifiers of Ab toxicity and they could promote APP internalization, endocytic trafficking, and Ab generation in neurons in vitro (Xiao et al. 2012; Treusch et al. 2011 ). Furthermore, several risk genes, e.g., SORL1, SLC24A4 and CD33, overlap with or are close to LncRNAs in genomic location, also suggesting the role of LncRNAs in AD. These hypotheses regarding LncRNAs and snRNAs should be tested in the future.
